We have 4 of 30 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Current evidence suggests that natural products should be repositioned from empirically derived cytotoxic candidates to mechanism-guided adjunctive agents for combination therapy in lymphoma.
Lung and prostate cancers were the most common OPMs in this cohort, highlighting the need for heightened clinical attention to these malignancies in patients with MM.
Overall, ASH 2025 suggests a shift from achieving gene editing to quantifying efficacy, durability, and safety, with standardized biomarker frameworks likely to play an increasingly important role in future clinical translation.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
